Tcr2 Therapeutics Inc (NASDAQ:TCRR) Expected to Post Earnings of -$0.55 Per Share

Share on StockTwits

Analysts expect that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will post ($0.55) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.52). The company is scheduled to announce its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Tcr2 Therapeutics will report full year earnings of ($5.27) per share for the current year, with EPS estimates ranging from ($6.50) to ($4.59). For the next year, analysts anticipate that the company will post earnings of ($2.56) per share, with EPS estimates ranging from ($2.99) to ($1.74). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Tcr2 Therapeutics.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.11.

Several equities analysts have recently weighed in on the stock. ValuEngine raised shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Roth Capital assumed coverage on shares of Tcr2 Therapeutics in a research note on Friday, May 31st. They issued a “neutral” rating and a $16.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating and set a $22.00 price target on the stock. in a research note on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Tcr2 Therapeutics currently has a consensus rating of “Buy” and an average price target of $26.83.

In other Tcr2 Therapeutics news, major shareholder Morana Jovan-Embiricos sold 64,104 shares of Tcr2 Therapeutics stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $17.11, for a total transaction of $1,096,819.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 39.07% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the business. EcoR1 Capital LLC purchased a new position in Tcr2 Therapeutics during the second quarter worth about $231,000. Laurion Capital Management LP purchased a new position in Tcr2 Therapeutics during the 1st quarter valued at about $417,000. Charles Schwab Investment Management Inc. purchased a new position in Tcr2 Therapeutics during the 2nd quarter valued at about $349,000. Parametric Portfolio Associates LLC grew its stake in Tcr2 Therapeutics by 23.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock valued at $501,000 after acquiring an additional 6,672 shares in the last quarter. Finally, Vanguard Group Inc. purchased a new position in Tcr2 Therapeutics during the 2nd quarter valued at about $1,070,000. 33.21% of the stock is currently owned by institutional investors.

Shares of NASDAQ:TCRR traded up $0.79 during midday trading on Friday, hitting $17.79. The company’s stock had a trading volume of 622 shares, compared to its average volume of 109,480. The business’s 50 day simple moving average is $16.98 and its 200 day simple moving average is $16.05. The company has a market cap of $405.99 million and a P/E ratio of -0.17. Tcr2 Therapeutics has a 12-month low of $10.04 and a 12-month high of $25.47.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Recommended Story: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.